📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Natural Capsules Subsidiary Signs ₹60 Cr Strategic CDMO Agreement with Fermbox Bio
Natural Biogenex, a material subsidiary of Natural Capsules Limited, has entered into a strategic framework agreement with Fermbox Bio to bolster fermentation-based CDMO capabilities. As part of the deal, Fermbox will provide equipment worth up to ₹60 crore at NBPL's Tumkur facility. This collaboration enables the company to target global biopharma and industrial biotech clients using advanced fermentation technology. The partnership is strategically timed to benefit from India's BioE3 Policy and the growing global demand for outsourced biomanufacturing.
Key Highlights
Natural Biogenex (NBPL) signs definitive agreements with Fermbox Bio for fermentation-based CDMO services.
Fermbox Bio to provide advanced equipment placement and technology worth up to ₹60 crore at NBPL’s Tumkur plant.
NBPL will handle GMP-compliant manufacturing, quality assurance, and regulatory compliance for the partnership.
The collaboration targets high-value segments in both pharmaceutical and industrial biotechnology.
The move aligns with the Indian government's BioE3 Policy to accelerate biomanufacturing innovation.
💼 Action for Investors
Investors should view this as a significant value-accretive step into high-margin CDMO services. Monitor the operationalization of the ₹60 crore equipment and the subsequent impact on the subsidiary's order book and margins.
Natural Capsules Subsidiary NBPL Signs Mfg Deal; Fermbox to Invest ₹60 Crore
Natural Biogenex Private Limited (NBPL), a material subsidiary of Natural Capsules Limited, has entered into a Framework and Contract Manufacturing agreement with Fermbox Bio Private Limited. Under this agreement, Fermbox will utilize the spare fermentation capacity of NBPL's plant. Significantly, Fermbox will invest up to ₹60 Crores in plant and machinery that will be owned by them but housed within NBPL's factory. This strategic move allows the company to monetize idle assets and leverage external capital for equipment, likely enhancing the subsidiary's operational throughput and revenue.
Key Highlights
Material subsidiary NBPL enters into a Framework & Contract Manufacturing agreement with Fermbox Bio.
Fermbox to invest up to ₹60 Crores in specialized plant and machinery at NBPL's facility.
The agreement aims to utilize the existing spare capacity of NBPL's fermentation plant.
Investment in machinery is funded by Fermbox while being integrated into NBPL's operational site.
The transaction is conducted at arm's length and does not involve related party interests.
💼 Action for Investors
Investors should monitor the execution timeline of the ₹60 Crore machinery installation and the resulting revenue growth in the subsidiary. This development is a positive indicator of better asset utilization and strategic partnership capabilities.
Natural Capsules Seeks Approval to Increase Investment and Loan Limits to ₹250 Crore
Natural Capsules Limited has issued a postal ballot notice to seek shareholder approval for increasing the limits of investments, loans, and guarantees under Section 186 of the Companies Act. The company is proposing a new aggregate limit of ₹250 Crore, which would allow the Board greater flexibility in capital deployment and inter-corporate financial support. The approval is being sought through a special resolution via electronic voting. This move suggests the company may be preparing for future expansions, acquisitions, or strategic investments.
Key Highlights
Proposed enhancement of limits for loans, investments, and guarantees to a maximum of ₹250 Crore.
Approval sought via Special Resolution through a Postal Ballot process conducted electronically.
E-voting period is scheduled from February 26, 2026, to March 27, 2026.
The cut-off date for determining shareholder eligibility for voting was February 20, 2026.
💼 Action for Investors
Investors should monitor the outcome of the vote and subsequent announcements to see how the company intends to utilize this significantly higher limit of ₹250 Crore. While it provides operational flexibility, the specific deployment of these funds will determine the long-term impact on shareholder value.
Natural Capsules Q3 FY26: Revenue drops 14% Y-o-Y to ₹37.75 Cr; Net Loss at ₹7.12 Cr
Natural Capsules reported a weak Q3 FY26 with consolidated revenue declining 14% Y-o-Y to ₹37.75 Cr, primarily due to a temporary regulatory shutdown of its Puducherry unit. The company posted a net loss of ₹7.12 Cr compared to a marginal profit in the previous year, as EBITDA margins crashed to -6.16% from 9.73% Y-o-Y. While the Puducherry plant has resumed operations and US tariffs on HPMC capsules have eased, the API fermentation block continues to face commercial scale-up challenges. Management is now exploring contractual partnerships to improve asset utilization and expects a recovery in Q4 FY26.
Key Highlights
Consolidated Revenue fell 14% Y-o-Y to ₹37.75 Cr due to regulatory issues and deferred dispatches at the Puducherry facility.
EBITDA turned negative at -₹2.33 Cr, with margins contracting by 1,589 bps Y-o-Y to -6.16%.
Net Loss for the quarter stood at ₹7.12 Cr, bringing the 9M FY26 total loss to ₹19.69 Cr.
US trade tariffs on HPMC capsules have been eased, restoring growth visibility in the North American market.
Company is in advanced talks with partners for contract manufacturing at its fermentation block to mitigate technical scale-up delays.
💼 Action for Investors
Investors should maintain a cautious stance given the significant bottom-line erosion and execution hurdles in the API segment. Monitor Q4 results closely to verify management's guidance on operational recovery and the finalization of fermentation block partnerships.
Natural Capsules Q3 Net Profit Crashes 79% YoY to ₹36 Lakhs; Allots 45,000 ESOP Shares
Natural Capsules reported a significant decline in financial performance for the quarter ended December 31, 2025. Standalone revenue fell 21% YoY to ₹34.15 crore, while net profit plummeted 79% YoY to just ₹0.36 crore. On a consolidated basis, the company barely broke even with a net profit of ₹0.10 crore. The board also approved the allotment of 45,000 equity shares under its ESOP scheme and is seeking to increase its investment limits via postal ballot.
Key Highlights
Standalone Net Profit declined sharply to ₹36.23 Lakhs from ₹170.32 Lakhs in the previous year's quarter.
Revenue from operations decreased to ₹3,414.64 Lakhs compared to ₹4,341.18 Lakhs YoY.
Consolidated Net Profit for Q3 FY26 stood at a marginal ₹10.33 Lakhs, down from ₹250.78 Lakhs in Q2 FY26.
Paid-up share capital increased to ₹10.38 Crore following the allotment of 45,000 ESOP shares at ₹10 each.
Board approved a postal ballot to enhance limits for loans and investments under Section 186 of the Companies Act.
💼 Action for Investors
The results show a severe deterioration in profitability and margins that warrants immediate caution. Investors should wait for management commentary to understand if these headwinds are transitory or structural before considering any new positions.
Natural Capsules Allots 45,000 ESOP Shares; Q3 Net Profit Drops to Rs 36.23 Lakhs
Natural Capsules Limited has allotted 45,000 equity shares following the exercise of options under its ESOP 2025 plan, increasing the paid-up capital to Rs 10.39 crore. However, the company's standalone financial results for Q3 FY25 show a significant downturn, with net profit plunging to Rs 36.23 lakhs from Rs 170.32 lakhs in the same quarter last year. Revenue from operations also declined to Rs 3,414.64 lakhs compared to Rs 4,341.18 lakhs YoY. Additionally, the board has approved a postal ballot to enhance limits for inter-corporate loans and investments under Section 186.
Key Highlights
Allotment of 45,000 equity shares at an exercise price of Rs 10 per share under ESOP 2025.
Standalone Net Profit for Q3 FY25 fell sharply to Rs 36.23 lakhs from Rs 170.32 lakhs YoY.
Revenue from operations decreased by approximately 21% YoY to Rs 3,414.64 lakhs.
Total paid-up share capital increased from Rs 10,34,11,540 to Rs 10,38,61,540.
Board approved seeking shareholder approval to enhance investment and loan limits under Section 186.
💼 Action for Investors
Investors should exercise caution as the company reports a substantial decline in both top-line and bottom-line performance for the December quarter. Monitor management's commentary on margin pressures and the strategic intent behind increasing investment limits.
Natural Capsules Q3 Net Profit Plummets 79% YoY to ₹36.23 Lakhs; Allots 45,000 ESOP Shares
Natural Capsules Limited reported a significantly weak performance for Q3 FY25, with revenue from operations dropping 21.3% YoY to ₹34.15 crore. Net profit witnessed a sharp decline of 78.7% YoY, falling to ₹36.23 lakhs from ₹1.70 crore in the year-ago period. On a sequential basis, profits fell nearly 87% from ₹2.81 crore in Q2 FY25. The company also approved the allotment of 45,000 equity shares under its ESOP scheme and is seeking shareholder approval to increase investment and loan limits.
Key Highlights
Revenue from operations declined to ₹3,414.64 lakhs in Q3 FY25 from ₹4,341.18 lakhs in Q3 FY24.
Net profit for the quarter stood at ₹36.23 lakhs, a massive drop from ₹281.04 lakhs in the preceding quarter.
Basic EPS fell sharply to ₹0.35 from ₹2.72 in Q2 FY25 and ₹1.65 in Q3 FY24.
Allotted 45,000 equity shares of ₹10 face value at an exercise price of ₹10 per share under ESOP 2025.
Board approved a Postal Ballot to enhance limits for loans, guarantees, and investments under Section 186 of the Companies Act.
💼 Action for Investors
Investors should exercise caution as the company shows significant margin compression and declining top-line growth. It is essential to monitor management's explanation for the profit slump and the intended use of the expanded investment limits.
Natural Capsules Q3 Net Profit Plummets 78% YoY to ₹36.23 Lakhs; Revenue Down 21%
Natural Capsules Limited reported a significant decline in financial performance for the quarter ended December 31, 2025. Standalone revenue from operations fell 21.3% YoY to ₹34.15 crore, while net profit saw a sharp 78.7% YoY drop to ₹0.36 crore. On a sequential basis, the profit decline was even steeper, falling 87% from ₹2.81 crore in Q2 FY26. The board also approved the allotment of 45,000 ESOP shares and is seeking to enhance investment limits under Section 186 of the Companies Act.
Key Highlights
Standalone Revenue from operations declined 21.3% YoY to ₹3,414.64 Lakhs from ₹4,341.18 Lakhs.
Net Profit crashed 78.7% YoY to ₹36.23 Lakhs compared to ₹170.32 Lakhs in the previous year's quarter.
Total expenses for the quarter stood at ₹3,579.48 Lakhs, leading to a significant compression in margins.
Allotted 45,000 equity shares of ₹10 each under the ESOP 2025 plan, increasing paid-up capital to ₹10.38 crore.
Board approved a Postal Ballot to increase limits for loans and investments under Section 186 of the Companies Act.
💼 Action for Investors
Investors should exercise caution as the company shows severe margin pressure and a sharp decline in both top and bottom lines. It is critical to wait for management commentary regarding the operational challenges that led to this significant quarterly underperformance.
Natural Capsules Subsidiary Cancels Rights Issue Due to Non-Subscription
Natural Capsules Limited's material subsidiary, Natural Biogenex Private Limited, has decided to cancel its planned Rights Issue. The decision was finalized during a board meeting on January 03, 2026, following the non-subscription of shares by the major shareholder. This Rights Issue was previously announced on September 30, 2025, and its cancellation indicates a setback in the subsidiary's capital raising efforts. Investors should note that this could impact the subsidiary's planned projects or debt management.
Key Highlights
Material subsidiary Natural Biogenex Private Limited cancels Rights Issue allotment.
Cancellation is attributed to non-subscription by the major shareholder.
The Rights Issue was originally initiated following an intimation on September 30, 2025.
Board decision to halt the process was made on January 03, 2026.
💼 Action for Investors
Investors should exercise caution and seek clarity on how the subsidiary intends to meet its funding requirements following this failed Rights Issue. Monitor for any further updates regarding the financial health or strategic direction of Natural Biogenex.
Natural Capsules Receives Temporary Closure Order for Pondicherry Plant
Natural Capsules Limited has been directed by the Department of Drug Controller to temporarily cease operations at its Pondicherry manufacturing plant as of December 26, 2025. The regulatory action was triggered by the company supplying material to a customer whose drug license had expired. While the company has initiated corrective actions and is seeking revocation of the order, the immediate halt in production poses an operational risk. The management is currently assessing the specific financial impact resulting from this shutdown.
Key Highlights
Department of Drug Controller ordered temporary closure of the Pondicherry plant on December 26, 2025
The regulatory violation involved supplying materials to a client with an expired drug license
Company has initiated corrective measures and is preparing documents for revocation of the order
Total financial impact of the operational halt is yet to be quantified by the management
💼 Action for Investors
Investors should remain cautious and monitor the company's updates regarding the restart of the Pondicherry plant. Any prolonged closure could significantly impact the upcoming quarterly production volumes and revenue.